#1 Clinical Trials Search in Europe

Etuvetidigene Autotemcel

Etuvetidigene Autotemcel is an innovative gene therapy being studied in clinical trials for the treatment of Wiskott-Aldrich Syndrome (WAS), a rare genetic disorder affecting the immune system. This article explores the ongoing research, potential benefits, and important aspects of this groundbreaking treatment approach for patients with WAS.

Table of Contents

What is Etuvetidigene Autotemcel?

Etuvetidigene Autotemcel, also known as OTL-103, is an advanced gene therapy medication designed to treat Wiskott-Aldrich Syndrome (WAS)[1]. This innovative treatment is a type of medicine called an autologous stem cell gene therapy. “Autologous” means it uses the patient’s own cells, and “gene therapy” refers to the process of modifying genes to treat a disease[2].

What Condition Does It Treat?

Etuvetidigene Autotemcel is specifically developed to treat Wiskott-Aldrich Syndrome (WAS). WAS is a rare genetic disorder that affects the immune system and blood cells. People with WAS often experience frequent infections, have difficulty with blood clotting, and may develop eczema (a type of skin inflammation)[1]. The condition is caused by mutations in the WAS gene, which is essential for the proper functioning of certain blood cells[2].

How Does It Work?

The treatment process for Etuvetidigene Autotemcel involves several steps:

  1. Doctors collect hematopoietic stem cells (blood-forming cells) from the patient. These are specifically CD34+ cells, which are capable of developing into various types of blood cells[1].
  2. In a laboratory, these cells are modified using a lentiviral vector. This vector is a specially designed virus that carries a correct copy of the WAS gene[2].
  3. The modified cells, now containing the functional WAS gene, are then given back to the patient through an intravenous infusion (a drip into a vein)[1].
  4. These modified cells can then produce normal blood cells, potentially correcting the underlying cause of WAS[2].

Clinical Trials and Research

Etuvetidigene Autotemcel is currently being studied in clinical trials to evaluate its safety and effectiveness. One ongoing study is a long-term follow-up of patients who received this treatment in earlier phase I/II trials[1]. Another is a phase III clinical trial evaluating a cryopreserved (frozen) formulation of the therapy[2].

These trials aim to assess several important factors:

  • The therapy’s ability to reduce severe infections and bleeding episodes[2]
  • Overall survival rates of treated patients[2]
  • Long-term safety, including monitoring for any delayed side effects[1]
  • The therapy’s impact on the immune system and blood cell production[1]
  • Quality of life improvements for patients[2]

Administration and Dosage

Etuvetidigene Autotemcel is administered as a single intravenous infusion. The dosage is typically measured in terms of cells, with a maximum dose of around 30 million cells per kilogram of the patient’s body weight[2]. The exact dose may vary depending on the individual patient and their condition.

Potential Benefits

If successful, this gene therapy could offer several benefits for patients with WAS:

  • Reduction in severe infections and bleeding episodes[2]
  • Improvement in overall immune system function[1]
  • Potential long-term correction of the genetic defect causing WAS[2]
  • Improved quality of life for patients[2]

Safety and Side Effects

As with any medical treatment, safety is a crucial concern. The clinical trials are closely monitoring patients for any adverse events (side effects). Some specific areas of focus include:

  • Monitoring for any signs of cancer or abnormal cell growth[2]
  • Checking for the presence of replication-competent lentivirus, which could potentially cause issues[2]
  • Long-term follow-up to detect any delayed side effects[1]

Ongoing Research

Research on Etuvetidigene Autotemcel is ongoing. Scientists are continuing to study its long-term effects, optimal dosing, and potential improvements to the therapy. Future studies may also explore its use in treating other related genetic conditions[1][2].

It’s important to note that while this therapy shows promise, it is still under investigation. Patients interested in this treatment should consult with their doctors and consider participating in clinical trials if appropriate.

Aspect Details
Treatment Name Etuvetidigene Autotemcel (OTL-103)
Condition Treated Wiskott-Aldrich Syndrome (WAS)
Type of Therapy Gene therapy using autologous CD34+ hematopoietic stem cells
Administration Single intravenous infusion
Primary Objectives Evaluate clinical efficacy in reducing severe infections and bleeding episodes
Secondary Objectives Assess overall survival, safety, engraftment, and quality of life improvements
Follow-up Duration Up to 15 years in long-term safety studies
Key Eligibility Criteria WAS diagnosis with genetic mutation, absent WASP expression, or severe clinical score
Safety Monitoring Adverse events, absence of malignancy or abnormal clonal proliferation, absence of replication-competent lentivirus

FAQ

  • What is Etuvetidigene Autotemcel? Etuvetidigene Autotemcel is a gene therapy that uses a patient's own modified blood stem cells to treat Wiskott-Aldrich Syndrome. It involves taking the patient's cells, adding a correct copy of the WAS gene using a special virus, and then returning these cells to the patient.
  • How is Etuvetidigene Autotemcel administered? The therapy is given as a single intravenous infusion. The modified cells are introduced into the patient's bloodstream, where they can then travel to the bone marrow and produce new, healthy blood cells.
  • What are the main goals of the clinical trials studying Etuvetidigene Autotemcel? The trials aim to evaluate the safety and effectiveness of the therapy. They're looking at how well it prevents severe infections and bleeding episodes, improves overall survival, and enhances the patient's quality of life.
  • Who is eligible for these clinical trials? Patients diagnosed with Wiskott-Aldrich Syndrome who have a genetic mutation, absent WASP expression, or a severe clinical score are generally eligible. However, those with certain conditions like active severe infections, malignancies, or prior gene therapy are typically excluded.
  • How long will patients be followed after receiving the treatment? Patients are typically followed for several years after receiving the treatment. In one study, patients are monitored for up to 15 years to assess long-term safety and effectiveness of the therapy.

Ongoing Clinical Trials on Etuvetidigene Autotemcel

  • Long-term Safety and Efficacy Study of Etuvetidigene Autotemcel for Patients with Wiskott-Aldrich Syndrome

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Long-Term Safety Study of Gene Therapy with Etuvetidigene Autotemcel for Patients with Wiskott-Aldrich Syndrome

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Use of OTL-103 Gene Therapy and Drug Combination for Patients with Wiskott-Aldrich Syndrome

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Wiskott-Aldrich Syndrome (WAS): A rare genetic disorder that affects the immune system, leading to recurrent infections, easy bruising, and bleeding.
  • Gene therapy: A technique that uses genes to treat or prevent disease. In this case, it involves adding a correct copy of the WAS gene to the patient's cells.
  • Lentiviral vector: A tool used in gene therapy to deliver genetic material into cells. It's made from a modified virus that can't cause disease.
  • CD34+ cells: A type of stem cell found in bone marrow that can develop into different types of blood cells.
  • Hematopoietic stem cell: Blood-forming stem cells that can develop into all types of blood cells, including white blood cells, red blood cells, and platelets.
  • Autologous: Using cells or tissues from the same individual. In this therapy, the patient's own cells are used.
  • Engraftment: The process by which transplanted stem cells start to grow and produce new, healthy blood cells in the body.
  • Replication-competent lentivirus (RCL): A potential safety concern in gene therapy where the modified virus used to deliver genes might regain the ability to replicate.
  • Vector copy number (VCN): A measure of how many copies of the therapeutic gene have been inserted into the patient's cells.
  • Insertional oncogenesis: A potential risk in gene therapy where the insertion of new genetic material could lead to the development of cancer.

References

  1. http://clinicaltrials.eu/trial/long-term-safety-study-of-gene-therapy-with-etuvetidigene-autotemcel-for-patients-with-wiskott-aldrich-syndrome/
  2. http://clinicaltrials.eu/trial/study-on-the-use-of-otl-103-gene-therapy-and-drug-combination-for-patients-with-wiskott-aldrich-syndrome/